Rizvi Qasim 4
4 · Kiniksa Pharmaceuticals, Ltd. · Filed Dec 9, 2019
Insider Transaction Report
Form 4
Rizvi Qasim
Chief Commercial Officer
Transactions
- Award
Class A Common Shares
2019-12-06+30,000→ 30,000 totalExercise: $10.61Exp: 2029-12-05→ Class A Common Shares (30,000 underlying)
Footnotes (1)
- [F1]The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is December 9, 2019.